Last edition
News about
Xtant Medical Extends Orthobiologics Portfolio, Launches CollagenX for Surgical Wound Closure
Xtant Medical Holdings has announced the commercial launch of CollagenX, a bovine collagen particulate product designed for surgical wound closure, extending its orthobiologics portfolio.
Acumed Expands CMF Capabilities with Acquisition of TECHFIT Digital Surgery Assets
Through the deal, Acumed gains full ownership of TECHFIT Digital Surgery's proprietary technologies, including its digital surgical planning and reconstruction platform.
Dynavax, Vaxart Enter Exclusive Global License Agreement for Novel Oral COVID-19 Vaccine
Under the terms of the agreement, Dynavax will receive exclusive, worldwide rights to develop and commercialise oral COVID-19 vaccines based on Vaxart’s delivery platform.
USFDA Grants ODD to Zydus' Desidustat for Beta-Thalassemia Treatment
Desidustat, a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), has received Orphan Drug Designation (ODD) from the USFDA. The designation grants eligibility for up to seven years of marketing exclusivity upon approval and highlights Desidustat’s potential to boost haemoglobin and red blood cell production.
WHO and Bayer Renew Partnership to Combat NTDs
The World Health Organization (WHO) and Bayer AG have renewed their partnership to combat Chagas disease, sleeping sickness, and taeniasis, with Bayer pledging USD 9.45 million to support WHO’s efforts through 2030.
Novo Nordisk Submits Updated Proposal to Acquire Metsera in Multi-Billion-Dollar Deal
Novo Nordisk has confirmed that it has submitted an updated, unsolicited proposal to acquire Metsera, which has been declared superior by Metsera’s board of directors.
AmacaThera, a leading biotechnology company specialising in next-generation hydrogel-based drug delivery systems, has entered into an exclusive global licensing agreement with Pacira BioSciences, Inc., a leader in non-opioid pain management, to develop and commercialise AMT-143.
FDA Grants ODD to Leukogene Therapeutics' M2T-CD33 (LTI-214) for Treating Acute Myeloid Leukemia
The US FDA has granted ODD to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the treatment of Acute Myeloid Leukemia (AML). The designation highlights the pressing need for new treatment options and acknowledges LTI-214’s potential as a novel and targeted therapy for this aggressive form of blood cancer.
Relonchem Gets MHRA Nod for Exemestane 25 mg Tablets
Exemestane by Relonchem, a subsidiary of Markans Pharma, is an aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. The approval marks another milestone in Marksans Pharma’s strategy to expand its oncology portfolio and strengthen its presence in the UK and European markets.
Zydus Gets USFDA Tentative Nod for Budesonide Delayed-Release Capsules, 4 mg
Zydus has received tentative approval from the US Food and Drug Administration (USFDA) for its Budesonide delayed-release capsules, 4 mg. The drug is indicated for the treatment of mild to moderate active Crohn’s disease affecting the ileum and/or ascending colon in adults and children aged eight years and above.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy